Keros Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
Business Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
Mailing Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
Phone
617-314-6297
Fiscal Year End
1231
EIN
811173868
Financial Overview
FY2025 FY
$243.86M
Revenue
$332.21M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4/A Insider transaction amendment | March 27, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 3 Initial insider ownership report | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| 10-K Annual financial report | March 4, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 26, 2026 | View on SEC |
Annual Reports
10-K
March 4, 2026
- Promising early clinical data for lead drug candidates KER-050 (MDS) and KER-012 (PAH).
- Strong cash position of $285.7 million with an estimated cash runway until mid-2027.
Insider Trading
SELL
5 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.